DexCom Files 8-K on Financials

Ticker: DXCM · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: DXCM

TL;DR

DexCom dropped an 8-K on Jan 13, 2025, with financial updates. Check it out.

AI Summary

DexCom, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report date and earliest event reported both being January 13, 2025. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing provides investors with updated information on DexCom's financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or immediate risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on DexCom, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

Where is DexCom, Inc. headquartered?

DexCom, Inc.'s principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.

What is DexCom, Inc.'s fiscal year end?

DexCom, Inc.'s fiscal year ends on December 31.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0001093557-25-000004.txt : 20250113 0001093557-25-000004.hdr.sgml : 20250113 20250113073158 ACCESSION NUMBER: 0001093557-25-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250113 DATE AS OF CHANGE: 20250113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25524814 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250113.htm 8-K dxcm-20250113 false 0001093557 0001093557 2025-01-13 2025-01-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025, beginning at 12:00 p.m. (Eastern Time), DexCom, Inc. (“Dexcom”) Chairman, President and Chief Executive Officer, Kevin Sayer, will report preliminary, unaudited financial results for the fourth quarter of 2024 and fiscal year 2024, initial financial outlook for fiscal year 2025, and certain other information. The fourth quarter and fiscal year 2024 preliminary unaudited financial results contained in Mr. Sayer’s presentation, the press release and this Current Report on Form 8-K are subject to finalization in connection with the preparation of Dexcom’s Annual Report on Form 10-K for the twelve months ended December 31, 2024. This Current Report on Form 8-K and the press release

View on Read The Filing